Bioventus (BVS) Revenue & Revenue Breakdown


OverviewForecastOwnershipFinancialsChartTranscripts

Bioventus Revenue Highlights


Latest Revenue (Y)

$512.35M

Latest Revenue (Q)

$151.22M

Main Segment (Y)

Pain Treatments

Main Geography (Y)

UNITED STATES

Bioventus Revenue by Period


Bioventus Revenue by Year

DateRevenueChange
2023-12-31$512.35M0.04%
2022-12-31$512.12M18.85%
2021-12-31$430.90M34.17%
2020-12-31$321.16M-5.58%
2019-12-31$340.14M6.57%
2018-12-31$319.18M25.83%
2015-12-31$253.65M4.43%
2014-12-31$242.89M4.53%
2013-12-31$232.38M258.75%
2000-01-01$64.77M-

Bioventus generated $512.35M in revenue during NA 2023, up 0.04% compared to the previous quarter, and up 160.52% compared to the same period a year ago.

Bioventus Revenue by Quarter

DateRevenueChange
2024-06-29$151.22M16.81%
2024-03-30$129.46M-4.41%
2023-12-31$135.42M12.11%
2023-09-30$120.79M-11.87%
2023-07-01$137.07M15.13%
2023-04-01$119.06M-5.38%
2022-12-31$125.83M-8.20%
2022-10-01$137.07M-2.32%
2022-07-02$140.33M19.64%
2022-04-02$117.29M-10.06%
2021-12-31$130.41M19.77%
2021-10-02$108.89M-0.84%
2021-07-03$109.82M34.29%
2021-04-03$81.78M-17.05%
2020-12-31$98.59M14.76%
2020-09-30$85.91M48.07%
2020-06-30$58.02M-26.23%
2020-03-31$78.64M-19.38%
2019-12-31$97.55M49.16%
2016-03-31$65.40M22.56%
2015-03-31$53.36M-

Bioventus generated $151.22M in revenue during Q2 2024, up 16.81% compared to the previous quarter, and up 127.01% compared to the same period a year ago.

Bioventus Revenue Breakdown


Bioventus Revenue Breakdown by Product

Annual Revenue by Product

Product/ServiceDec 21
Restorative Therapies$121.57M
Pain Treatments$221.61M
Surgical Solutions$87.72M

Bioventus's latest annual revenue breakdown by segment (product or service), as of Dec 21: Pain Treatments (51.43%), Restorative Therapies (28.21%), and Surgical Solutions (20.36%).

Quarterly Revenue by Product

Product/ServiceJun 24Mar 24Jul 22Apr 22Dec 21Oct 21Jul 21Apr 21
International Segment$16.81M$15.18M------
U.S. Segment$134.41M$114.28M------
Surgical Solutions--$36.52M$30.88M----
Pain Treatments--$63.91M$52.05M----
Restorative Therapies--$39.90M$34.36M$36.77M$30.48M$32.51M$21.82M
Pain Treatments And Joint Preservation-----$60.63M$56.70M$41.53M
Bone Graft Substitutes-----$17.78M$20.60M$18.43M

Bioventus's latest quarterly revenue breakdown by segment (product or service), as of Jun 24: U.S. Segment (88.88%), and International Segment (11.12%).

Bioventus Revenue Breakdown by Country

Annual Revenue by Country

CountryDec 23Dec 22Dec 21
Non-US$62.48M$14.95M$43.34M
UNITED STATES$449.86M$126.21M$387.55M

Bioventus's latest annual revenue breakdown by geography, as of Dec 23: UNITED STATES (87.80%), and Non-US (12.20%).

Quarterly Revenue by Country

CountryJun 24Mar 24Dec 23Jul 23Dec 22Oct 22Jul 22Apr 22Dec 21Oct 21Jul 21Apr 21
Non-US$16.81M$15.18M$26.90M$5.42M$4.41M$3.24M$14.02M$13.21M$15.24M$9.73M$11.13M$7.24M
UNITED STATES$134.41M$114.28M$208.52M$33.39M$34.94M$31.18M$126.31M$104.08M$115.17M$99.16M$98.68M$74.54M

Bioventus's latest quarterly revenue breakdown by geography, as of Jun 24: UNITED STATES (88.88%), and Non-US (11.12%).

Bioventus Peer Comparison by Revenue


TickerCompanyLast Year RevenueLast Quarter Revenue
BVSBioventus$512.35M$151.22M
RPIDRapid Micro Biosystems$22.52M$6.62M
HSCSHeart Test Laboratories$18.60M-
VVOSVivos Therapeutics$13.80M$4.05M
NUWENuwellis$8.86M$2.19M
NAOVNanoVibronix$2.28M$817.00K
TIVCTivic Health Systems$1.18M$140.00K
BJDXBluejay Diagnostics--
BBLGBone Biologics--

BVS Revenue FAQ


Bioventus's yearly revenue for 2023 was $512.34M, representing an increase of 0.04% compared to 2022. The company's yearly revenue for 2022 was $512.12M, representing an increase of 18.85% compared to 2021. BVS's yearly revenue for 2021 was $430.9M, representing an increase of 34.17% compared to 2020.

Bioventus's quarterly revenue for Q2 2024 was $151.22M, a 16.81% increase from the previous quarter (Q1 2024), and a 10.32% increase year-over-year (Q2 2023). The company's quarterly revenue for Q1 2024 was $129.46M, a -4.41% decrease from the previous quarter (Q4 2023), and a 8.73% increase year-over-year (Q1 2023). BVS's quarterly revenue for Q4 2023 was $135.42M, a 12.11% increase from the previous quarter (Q3 2023), and a 7.62% increase year-over-year (Q4 2022).

Bioventus's revenue growth rate for the last 3 years (2021-2023) was 18.90%, and for the last 5 years (2019-2023) was 50.63%.

Bioventus's revenue streams in c 21 are Restorative Therapies, Pain Treatments, and Surgical Solutions. Restorative Therapies generated $121.57M in revenue, accounting 28.21% of the company's total revenue Pain Treatments generated $221.61M in revenue, accounting 51.43% of the company's total revenue Surgical Solutions generated $87.72M in revenue, accounting 20.36% of the company's total revenue

For the fiscal year ending Dec 21, the largest source of revenue of Bioventus was Pain Treatments. This segment made a revenue of $221.61M, representing 51.43% of the company's total revenue.